The Food and Drug Administration (FDA) has raised significant concerns regarding 7-hydroxymitragynine, commonly referred to as 7-OH, highlighting its potential dangers as it is found in various consumer products across the United States, including gas stations and convenience stores. This potent substance, derived from kratom, is reported to be 13 times more potent than morphine and poses serious health risks due to its classification as an opioid.
Dr. Marty Makary, the FDA Commissioner, emphasized that 7-OH, a synthetic byproduct of kratom, shares similar chemical properties with some of the most dangerous drugs, indicating a high potential for addiction and abuse. HHS Secretary Robert F. Kennedy, Jr. has advocated for the substance to be listed as a Class 1 Controlled Substance, aligning it with drugs like heroin and LSD, reflecting increasing governmental concern over its accessibility.
Senator Markwayne Mullin from Oklahoma has voiced his worries as well, sharing insights from his experiences with addiction and stating, “It’s an addiction that’s ruining lives,” pointing to tragic outcomes associated with its use.
In light of these concerns, the FDA has begun proactive measures by sending warning letters to companies promoting 7-OH products and collaborating with the Drug Enforcement Administration (DEA) to reclassify this substance to prevent potential public health crises similar to the opioid epidemic.
Dr. Makary warned of an impending issue, calling it “the calm before the storm” and stressing the importance of public education to mitigate the effects of this rising trend. The FDA is providing resources on their website for those seeking more information on the risks connected with 7-OH.
Overall, authorities are making efforts to tackle the potential threat posed by 7-OH, showcasing a determined stance to address the possible challenges before they escalate. It’s a reminder of the importance of awareness and caution when it comes to emerging substances in the market.